Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | CA5A | P35218 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44393 | 0.83 | ATM (0.70) | KDM4EATMCA2CA1CA9 | |
| SCHEMBL19409880 | 0.83 | ATM (0.70) | KDM4EATMCA2CA1CA9 | |
| SCHEMBL29535675 | 0.83 | ATM (0.70) | KDM4EATMCA2CA1CA9 | |
| Hydrochloric Acid SCHEMBL9726669 | 0.81 | ATM (0.68) | KDM4EATMCA2CA1CA9 | |
| SCHEMBL5758819 | 0.79 | SMN1; SMN2 (0.46) | KDM4EATMCA2CA1CA9 | |
| SCHEMBL27745086 | 0.79 | PSIP1 (0.35) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL28773170 | 0.79 | PTPN1 (0.37) | KDM4ECA2CA1CA9CA5A | |
| SCHEMBL13593083 | 0.79 | TUBB4A (0.60) | KDM4ECA2CA1CA9CA5A | |
| Hydrochloric Acid SCHEMBL4968998 | 0.79 | PTPN1 (0.38) | CA2CA1CA9PTPN1MAPT | |
| SCHEMBL14873024 | 0.77 | MAPT (0.49) | KDM4ESMN1; SMN2CYP19A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049773-A1 | Process for functionalising a phenolic compound carrying an electron-donating group | MIOSKOWSKI CHARLES | 2007-03-01 | — | — | US | disclosed |
| US-20070049773-A1 | Process for functionalising a phenolic compound carrying an electron-donating group | MIOSKOWSKI CHARLES | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049773-A1 | Process for functionalising a phenolic compound carrying an electron-donating group | COMT, ETFA, LPO | KDM4E 1786/4885ATM 1846/4885CA2 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.